PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
4.88%
Growth of 4.88% versus flat Medical - Pharmaceuticals revenue. Walter Schloss would verify growth quality.
4.66%
Cost growth of 4.66% versus flat Medical - Pharmaceuticals costs. Walter Schloss would verify cost control.
5.75%
Growth of 5.75% versus flat Medical - Pharmaceuticals gross profit. Walter Schloss would verify quality.
0.82%
Margin expansion while Medical - Pharmaceuticals median declines. Peter Lynch would examine competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
G&A reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate efficiency gains.
-100.00%
Marketing expense reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate competitive implications.
-15.87%
Other expenses reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate advantages.
4.04%
Operating expenses growth while Medical - Pharmaceuticals reduces costs. Peter Lynch would examine differences.
4.55%
Total costs growth while Medical - Pharmaceuticals reduces costs. Peter Lynch would examine differences.
No Data
No Data available this quarter, please select a different quarter.
-3.42%
D&A reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate efficiency.
6.13%
EBITDA growth 75-90% of Medical - Pharmaceuticals median of 7.88%. John Neff would investigate potential.
1.19%
EBITDA margin growth below 50% of Medical - Pharmaceuticals median of 5.06%. Jim Chanos would check for deterioration.
12.67%
Operating income growth exceeding 1.5x Medical - Pharmaceuticals median of 4.31%. Joel Greenblatt would investigate advantages.
7.43%
Operating margin growth 1.25-1.5x Medical - Pharmaceuticals median of 5.06%. Mohnish Pabrai would examine sustainability.
-9.44%
Other expenses reduction while Medical - Pharmaceuticals median is 11.11%. Seth Klarman would investigate advantages.
10.75%
Pre-tax income growth near Medical - Pharmaceuticals median of 10.75%. Charlie Munger would verify industry dynamics.
5.60%
Pre-tax margin growth 75-90% of Medical - Pharmaceuticals median of 6.32%. John Neff would investigate potential.
58.92%
Tax expense growth exceeding 1.5x Medical - Pharmaceuticals median of 24.96%. Jim Chanos would check for issues.
-3.27%
Net income decline while Medical - Pharmaceuticals median is 2.20%. Seth Klarman would investigate causes.
-7.77%
Net margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-3.27%
EPS decline while Medical - Pharmaceuticals median is 2.40%. Seth Klarman would investigate causes.
-3.27%
Diluted EPS decline while Medical - Pharmaceuticals median is 3.07%. Seth Klarman would investigate causes.
-0.00%
Share count reduction while Medical - Pharmaceuticals median is 0.14%. Seth Klarman would investigate strategy.
-0.00%
Diluted share reduction while Medical - Pharmaceuticals median is 0.12%. Seth Klarman would investigate strategy.